Roles of Sema4A in multiple sclerosis and interferon‐β therapy efficacy

Abstract

The early initiation of appropriate treatment is important for a better prognosis for patients with multiple sclerosis (MS). Although interferon (IFN-b) has been the most prescribed therapy for MS, some patients are poor responders to this therapy. Therefore, finding biomarkers to predict treatment responsiveness is required. Some patients with MS have high serum Sema4A and concurrently have characteristics of Th17-skewing conditions, and do not respond well to IFN-b therapy. In the present review, we discuss Sema4A and responsiveness to IFN-b therapy. In addition, we review biomarkers relevant to IFN-b therapy responsiveness. (Clin. Exp. Neuroimmunol